|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5457
|
|
pubmed:dateCreated |
2000-3-13
|
|
pubmed:abstractText |
The brain is generally considered immunoprivileged, although increasing examples of immunological responses to brain antigens, neuronal expression of major histocompatibility class I genes, and neurological autoimmunity have been recognized. An adeno-associated virus (AAV) vaccine generated autoantibodies that targeted a specific brain protein, the NR1 subunit of the N-methyl-D-aspartate (NMDA) receptor. After peroral administration of the AAV vaccine, transgene expression persisted for at least 5 months and was associated with a robust humoral response in the absence of a significant cell-mediated response. This single-dose vaccine was associated with strong anti-epileptic and neuroprotective activity in rats for both a kainate-induced seizure model and also a middle cerebral artery occlusion stroke model at 1 to 5 months following vaccination. Thus, a vaccination strategy targeting brain proteins is feasible and may have therapeutic potential for neurological disorders.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
0036-8075
|
|
pubmed:author |
pubmed-author:DickerB LBL,
pubmed-author:DunningJJ,
pubmed-author:DuringM JMJ,
pubmed-author:FitzsimonsH LHL,
pubmed-author:GuoH FHF,
pubmed-author:LawlorP APA,
pubmed-author:LeoniLL,
pubmed-author:LipskiJJ,
pubmed-author:LisMM,
pubmed-author:PoulsenDD,
pubmed-author:SymesC WCW,
pubmed-author:YoungDD
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
25
|
|
pubmed:volume |
287
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1453-60
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:10688787-Administration, Oral,
pubmed-meshheading:10688787-Animals,
pubmed-meshheading:10688787-Antibody Affinity,
pubmed-meshheading:10688787-Autoantibodies,
pubmed-meshheading:10688787-Blood-Brain Barrier,
pubmed-meshheading:10688787-Dependovirus,
pubmed-meshheading:10688787-Epilepsy, Temporal Lobe,
pubmed-meshheading:10688787-Epitope Mapping,
pubmed-meshheading:10688787-Epitopes,
pubmed-meshheading:10688787-Genetic Vectors,
pubmed-meshheading:10688787-Hippocampus,
pubmed-meshheading:10688787-Intestinal Mucosa,
pubmed-meshheading:10688787-Lymphocyte Activation,
pubmed-meshheading:10688787-Motor Activity,
pubmed-meshheading:10688787-Rats,
pubmed-meshheading:10688787-Receptors, N-Methyl-D-Aspartate,
pubmed-meshheading:10688787-Status Epilepticus,
pubmed-meshheading:10688787-Stroke,
pubmed-meshheading:10688787-Transgenes,
pubmed-meshheading:10688787-Vaccination,
pubmed-meshheading:10688787-Vaccines, DNA
|
|
pubmed:year |
2000
|
|
pubmed:articleTitle |
An oral vaccine against NMDAR1 with efficacy in experimental stroke and epilepsy.
|
|
pubmed:affiliation |
Department of Molecular Medicine and Department of Physiology, University of Auckland School of Medicine, Auckland, New Zealand. matthew.during@mail.tju.edu
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
